NYSEAM:YMI - Post by User
Comment by
DutchGoldMineon Sep 07, 2009 5:31pm
442 Views
Post# 16284501
RE: Efficacy
RE: Efficacycome on DYOR for instance look at the news release of 6/23/2009 and you find this:
Results were reported recently at the 2009 ASCO Annual Meeting from arandomized Phase IIb, four-arm, open-label trial of nimotuzumab incombination with radiation therapy (RT) or chemoradiation therapy (CRT)in patients with inoperable, locoregionally advanced Stage III/IVa headand neck cancer conducted in India by Reddy BK et al. The addition ofnimotuzumab to both the RT and CRT regimens improved the overallresponse rate, survival rate at 30 months, median progression-freesurvival and median overall survival. A combined group analysis of thenimotuzumab arms vs. the non-nimotuzumab arms demonstrated asignificant difference in overall survival (p = 0.0018) favoringnimotuzumab. The addition of nimotuzumab did not add to the toxicitiesof either regimen, with no Grade III/IV skin toxicities observed. Thetrial demonstrates that the efficacy of nimotuzumab compares favorablyto results reported for cetuximab, an EGFR-targeting antibody marketedas Erbitux(R), but that this efficacy was not accompanied by the severetoxicities reported in patients treated with cetuximab.